NASDAQ:ONC BeOne Medicines Q4 2024 Earnings Results & Report $349.08 -1.32 (-0.38%) Closing price 04:00 PM EasternExtended Trading$349.30 +0.22 (+0.06%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. BeOne Medicines missed analyst earnings expectations but beat on revenue in its Q4 2024 results, released February 27, 2025. The company reported EPS of -$1.43 versus the -$0.88 consensus estimate, while revenue of $1.13 billion topped the $1.09 billion estimate by $40.85 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateFebruary 27, 2025TimeBefore Market Opens BeOne Medicines EPS ResultsActual EPS-$1.43Consensus EPS -$0.88Beat/MissMissed by -$0.55One Year Ago EPSN/AEPS Beat Rate3 of last 5 quartersBeOne Medicines Revenue ResultsActual Revenue$1.13 billionExpected Revenue$1.09 billionBeat/MissBeat by +$40.85 millionYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile BeOne Medicines Q4 2024 Earnings FAQ Did BeOne Medicines beat earnings estimates for Q4 2024? BeOne Medicines (NASDAQ:ONC) reported earnings of -$1.43 per share for Q4 2024, missing the consensus estimate of -$0.88. The report was announced on Thursday, February 27, 2025. What was BeOne Medicines' revenue for Q4 2024? BeOne Medicines reported revenue of $1.13 billion for Q4 2024, against a consensus estimate of $1.09 billion. BeOne Medicines Earnings HeadlinesBeOne Medicines (ONC) Surged on Strong Financial Performance and Upgraded GuidanceOctober 13 at 8:31 AM | insidermonkey.comBeOne Medicines (NASDAQ:ONC) Stock Gets Price Target Bump from Royal Bank Of CanadaOctober 10 at 3:18 AM | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 13 at 1:00 AM | Porter & Company (Ad)Truist Financial Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) StockOctober 9, 2026 | americanbankingnews.comBeOne Medicines AG (ONC)October 8, 2026 | finance.yahoo.comBeOne Medicines (NASDAQ:ONC) Stock Rating Lowered by Zacks ResearchOctober 7, 2026 | americanbankingnews.comSee More BeOne Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email. Email Address About BeOne MedicinesBeOne Medicines (NASDAQ:ONC) Ltd. (NASDAQ: ONC) is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for people with cancer. The company operates across the research and development, clinical testing, regulatory and commercial stages of the biopharmaceutical industry, with an emphasis on treatments for blood cancers and solid tumors. Its marketed portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat several B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy targeting the PD-1 pathway for certain cancers. BeOne also has a pipeline of investigational therapies designed to address additional hematologic and solid-tumor indications. The company was founded in 2010 as BeiGene and adopted the BeOne Medicines name as part of its evolution into a global oncology-focused business. It serves patients and healthcare providers in China, the United States, Europe and other international markets. John V. Oyler, the company’s founder, serves as chief executive officer.View BeOne Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
